Contact Information: CONTACTS: Warren Lancaster +1-203-966-2556 (USA) David Sheon +1 202 547-2880 (USA)
Researchers Discover That Phenoxodiol Kills Rapidly Proliferating T-Cells
| Source: Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - July 7, 2009) - Researchers at the
Malaghan Institute of Medical Research in Wellington, New Zealand have
found that abnormally proliferating human T-cells, rapidly dividing cancer
cells such as primary myeloid and lymphoid leukemic blast cells undergo
programmed cell death when exposed briefly to the investigational
anti-tumor drug phenoxodiol.
These results make phenoxodiol a promising candidate for the treatment of
pathologically activated lymphocytes such as those in acute lymphoid
leukemia, or diseases driven by T-cell proliferation such as autoimmune
diseases and graft-versus-host disease, according to an article published
in the Haematologica Journal on June 16, 2009,
http://www.haematologica.org/cgi/reprint/94/7/928.
The researchers demonstrated that phenoxodiol inhibited plasma membrane
electron transport and cell proliferation and promoted apoptosis of rapidly
proliferating human T-cells, induced to undergo rapid proliferation by
exposure to cells from an incompatible donor, but at the same time it did
not affect normal resting T-cells.
"These findings indicate that phenoxodiol may have utility against
autoimmune diseases, such as rheumatoid arthritis and psoriasis, as well as
having potential in management of graft rejection in transplantation
patients," said Prof. Alan Husband, Group Director of Research, Marshall
Edwards, Inc. "We're appreciative of Dr. Patries Herst and colleagues for
undertaking this important research."
About phenoxodiol
Phenoxodiol is being developed by the U.S. oncology company Marshall
Edwards, Inc. (NASDAQ : MSHL ) as a chemosensitizing agent in combination
with platinum drugs for late stage, chemoresistant ovarian cancer and as a
monotherapy for prostate and cervical cancers. It has a unique mechanism of
action, binding to cancer cells via a surface oxidase, disrupting membrane
electron transport and causing major downstream disturbances in expression
of proteins necessary for cancer cell survival and responsible for the
development of drug resistance.
In cancer cells, phenoxodiol appears to inhibit selectively the
pro-survival regulator known as S-1-P (sphingosine-1-phosphate) that is
overexpressed in cancer cells. In response to phenoxodiol, the S-1-P
content in cancer cells is decreased, rendering those cells more sensitive
to chemotherapy. Indeed, in laboratory studies, it has been demonstrated
that cancer cells pre-treated with phenoxodiol were killed with lower doses
of chemotherapy drugs.
Importantly, phenoxodiol has been shown not to affect adversely normal
cells in animal and laboratory testing. Phenoxodiol is being investigated
as a therapy for late-stage, chemoresistant ovarian, prostate and cervical
cancers. Phenoxodiol has received Fast Track status from the FDA to
facilitate its development as a therapy for recurrent ovarian and prostate
cancers. Phenoxodiol is an investigational drug and, as such, is not
commercially available. Under U.S. law, a new drug cannot be marketed until
it has been investigated in clinical trials and approved by FDA as being
safe and effective for the intended use.
Phenoxodiol is the first of a family of compounds in the Marshall Edwards,
Inc. drug pipeline of flavonoid derivatives.
About Marshall Edwards, Inc.
Marshall Edwards, Inc. is a specialist oncology company focused on the
clinical development of novel anti-cancer therapeutics. These derive from
a flavonoid technology platform, which has generated a number of novel
compounds characterized by broad ranging activity against a range of cancer
cell types with few side effects. The combination of anti-tumor cell
activity and low toxicity is believed to be a result of the ability of
these compounds to target an enzyme present in the cell membrane of cancer
cells, thereby inhibiting the production of pro-survival proteins within
the cell. Marshall Edwards has licensed rights from Novogen Limited (ASX : NRT ) (NASDAQ : NVGN ) to bring three oncology drugs -- phenoxodiol,
triphendiol and NV-143 -- to market globally.
Marshall Edwards is majority owned by Novogen (ASX : NRT ) (NASDAQ : NVGN ), an
Australian biotechnology company that is specializing in the development of
therapeutics based on a flavonoid technology platform. Novogen is
developing a range of therapeutics across the fields of oncology,
cardiovascular disease and inflammatory diseases. More information on
phenoxodiol and on the Novogen group of companies can be found at
www.marshalledwardsinc.com and www.novogen.com.
Under U.S. law, a new drug cannot be marketed until it has been
investigated in clinical trials and approved by the FDA as being safe and
effective for the intended use. Statements included in this press release
that are not historical in nature are "forward-looking statements" within
the meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. You should be aware that our actual results
could differ materially from those contained in the forward-looking
statements, which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not limited
to, our failure to successfully commercialize our product candidates; costs
and delays in the development and/or FDA approval, or the failure to obtain
such approval, of our product candidates; uncertainties in clinical trial
results; our inability to maintain or enter into, and the risks resulting
from our dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization, marketing,
sales and distribution of any products; competitive factors; our inability
to protect our patents or proprietary rights and obtain necessary rights to
third party patents and intellectual property to operate our business; our
inability to operate our business without infringing the patents and
proprietary rights of others; general economic conditions; the failure of
any products to gain market acceptance; our inability to obtain any
additional required financing; technological changes; government
regulation; changes in industry practice; and one-time events. We do not
intend to update any of these factors or to publicly announce the results
of any revisions to these forward-looking statements.